BOSTON, July 1 /PRNewswire/ — China PharmaHub
Corp. (“PharmaHub”), announced today that it has entered into a
definitive agreement with Dr. David
Weaver and Dr. Michael
Rynkiewicz. In addition, PharmaHub contemplates
merging with World Wide Relics, Inc. (OTC Bulletin Board: WRLC) of
which it recently purchased a 77% interest.
The management of World Wide Relics (“WWR”) and PharmaHub are
looking forward to the potential merger and are working diligently
towards it. PharmaHub is engaged in the business of
licensing, development and commercialization of pharmaceutical and
healthcare products and technologies between Chinese pharmaceutical
companies and other pharmaceutical companies located worldwide,
with initial emphasis in the United
States and Europe. For
existing WWR shareholders, the merger could add substantial value
due to PharmaHub’s existing business relationships and agreements.
Pursuant to PharmaHub’s agreement with Dr. Weaver and Dr.
Rynkiewicz, a joint venture has been created and will be known as
Akanas Therapeutics, Inc. (“Akanas”), of which PharmaHub owns a 35%
interest. The joint venture will have the exclusive rights to
the intellectual property, which includes patents on a proprietary
technology using atomic structure for antibody humanization to
rapidly and cost-effectively create humanized antibodies which
retain high affinity and avoid immunogenicity. Dr. Weaver and
Dr. Rynkiewicz invented the core Akanas platform technology in
2005. Dr. Weaver has over 15 years of experience in the
research and development of cancer biology and immunology. He
received postgraduate training at MIT
and the Whitehead Institute
‘/>”/>
